Chioma Obiokoye, MD
Advanced Heart Failure and Transplant Cardiology · Louisville, KYNPI 1942682232
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,392 of the $13,553 with a category attached, or 69.3%. E.r. Squibb & Sons, L.L.C. accounts for 76.9% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $10,922, more than ten times the $314 reported in 2021.
Across 65 payments — averaging $208.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$10K
- Abbott$2K
- Medtronic$179
- Atricure, Inc.$146
- Abiomed$143
- Pfizer$142
- plus $746 from 9 others
Across 51 payments — averaging $1249.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$34K
- Boehringer Ingelheim International GmbH$23K
- Boehringer Ingelheim Pharma GmbH & Co.kg$7K
What the payments were for
- Consulting fees$3002%
- Speaking & faculty fees$9,39269%
- Grants$1141%
- Travel & lodging$6605%
- Food & beverage$2,92022%
- Education$1671%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 15 | $10,421 |
| Abbott | 20 | $1,776 |
| Medtronic | 2 | $179 |
| Atricure, Inc. | 1 | $146 |
| Abiomed | 1 | $143 |
| Pfizer | 3 | $142 |
| Vital Connect, Inc | 1 | $125 |
| Scpharmaceuticals Inc. | 1 | $121 |
| Lexicon Pharmaceuticals, Inc. | 1 | $120 |
| Boston Scientific | 1 | $118 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $90 |
| Gilead | 5 | $76 |
| Esperion Therapeutics, Inc. | 4 | $68 |
| Novartis | 1 | $15 |
| Ancora Heart, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$10,165
- CARDIOMEMS$790
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$207
- ENSITE PRECISION$167
- ATRICLIP LAA EXCLUSION SYSTEM$146
- VITALPATCH RTM$125
- FUROSCIX$121
- Inpefa$120
- Watchman$118
- VYNDAQEL$109
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$105
How this compares
Too few advanced heart failure and transplant cardiology providers in Kentuckyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 100 | $815,518 |
| EntrestoSacubitril/Valsartan | 173 | $188,054 |
| JardianceEmpagliflozin | 120 | $130,957 |
| FarxigaDapagliflozin Propanediol | 36 | $31,208 |
| Metoprolol Succinate | 227 | $2,691 |
| Bumetanide | 78 | $2,369 |
| Spironolactone | 205 | $1,375 |
| Midodrine Hcl | 12 | $1,102 |
| Carvedilol | 124 | $966 |
| Torsemide | 31 | $635 |
| Potassium Chloride | 23 | $600 |
| Ranolazine ErRanolazine | 13 | $506 |
| Digoxin | 15 | $409 |
| Atorvastatin Calcium | 31 | $354 |
| Furosemide | 112 | $324 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $10,421 | $815,518100 claims |
| NovartisEntresto | $15 | $188,054173 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Kentuckyon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Louisville
- Sonali AroraLouisville$1K
- Timothy RaymondFt Wright$88K
- Sonu AbrahamLexington$13K
- Marciano LeeLexington$11K
- Hareeprasad VongooruEdgewood$8K
- Amaninderapal GhotraEdgewood$8K
- Andrew KolodziejLexington$7K
- Navin RajagopalanLexington$6K
- Maya IgnaszewskiLexington$6K
- Keerthy NarisettyEdgewood$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.